Clinical Edge Journal Scan

Nailfold capillary abnormalities predict PsA in patients with psoriasis


 

Key clinical point: Nailfold capillary abnormalities were more prevalent in patients with psoriatic arthritis (PsA) than in patients with psoriasis vulgaris (PsV) and predicted the development of PsA in patients with psoriasis.

Major finding: Nailfold bleeding (NFB; 84.5% vs 34.7%) and enlarged capillaries ( 100.0% vs 25.4%; both P < .0001) were more prevalent in patients with PsA vs PsV, with both NFB (hazard ratio [HR] 2.75; P = .004) and enlarged capillaries (HR 4.49; P < .0001) predicting the development of PsA in patients with PsV.

Study details: Findings are from a prospective cohort study including 236 patients with PsV and 213 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fukasawa T et al. Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study. Rheumatology (Oxford). 2022 (Nov 28). Doi: 10.1093/rheumatology/keac664

Recommended Reading

Q-DAPSA based on C-reactive protein assays in agreement with DAPSA
Psoriatic Arthritis ICYMI
Serum calprotectin: A promising biomarker in PsA
Psoriatic Arthritis ICYMI
Treg cells and serum Treg-associated cytokines play an important role in PsA pathogenesis
Psoriatic Arthritis ICYMI
Wide variance described in lab monitoring of conventional synthetic DMARDs
Psoriatic Arthritis ICYMI
Skinny-label biosimilars provide substantial savings to Medicare
Psoriatic Arthritis ICYMI
Commentary: Sex differences, pregnancy, a quicker CRP test, and new drugs in PsA, December 2022
Psoriatic Arthritis ICYMI
Vaccination cuts long COVID risk for rheumatic disease patients
Psoriatic Arthritis ICYMI
Bimekizumab shows promise in PsA patients naive to bDMARD
Psoriatic Arthritis ICYMI
BNT162b2 booster dose highly recommended for PsA patients on TNF inhibitors
Psoriatic Arthritis ICYMI
Bimekizumab beneficial in PsA patients with inadequate response to or intolerance of TNFα inhibitors
Psoriatic Arthritis ICYMI